C/EBP ζ targets to neutrophil gelatinase-associated lipocalin (NGAL) as a repressor for metastasis of MDA-MB-231 cells

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1813, Issue 10, 2011, Pages 1803-1813

  Wang, Lihong ^a   Li, Huawen ^a   Wang, Jian ^a   Gao, Wei ^a   Lin, Yani ^a   Jin, Weina ^a   Chang, Guoqiang ^a   Wang, Ruojun ^a   Li, Qinghua ^a   Ma, Li ^a   Pang, Tianxiang ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

Breast cancer; C EBP ; Metastasis; Neutrophil gelatinase associated lipocalin

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN; CCAAT ENHANCER BINDING PROTEIN ZETA; LUCIFERASE; MATRIX METALLOPROTEINASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; REPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INVASION; CELL MIGRATION; CELL STRAIN MCF 7; CELL STRAIN MDA MB 231; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

ACUTE-PHASE PROTEINS; BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; JURKAT CELLS; K562 CELLS; LIPOCALINS; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; TRANSCRIPTION FACTOR CHOP; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 80051797995     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2011.06.010     Document Type: Article

References (43)

1. Wang X., Lu H., Urvalek A.M., Li T., Yu L., Lamar J., Dipersio C.M., Feustel P.J., Zhao J. KLF8 promotes human breast cancer cell invasion and metastasis by transcriptional activation of MMP9. Oncogene 2010, 30:1901-1911.
2. Fougere M., Gaudineau B., Barbier J., Guaddachi F., Feugeas J.P., Auboeuf D., Jauliac S. NFAT3 transcription factor inhibits breast cancer cell motility by targeting the Lipocalin 2 gene. Oncogene 2010, 29:2292-2301.
3. Sporn M.B. The war on cancer. Lancet 1996, 347:1377-1381.
4. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
5. LaPensee E.W., LaPensee C.R., Fox S., Schwemberger S., Afton S., Ben-Jonathan N. Bisphenol A and estradiol are equipotent in antagonizing cisplatin-induced cytotoxicity in breast cancer cells. Cancer Lett. 2010, 290:167-173.
6. Akerstrom B., Flower D.R., Salier J.P. Lipocalins: unity in diversity. Biochim. Biophys. Acta 2000, 1482:1-8.
7. Deroo B.J., Korach K.S. Estrogen receptors and human disease. J. Clin. Invest. 2006, 116:561-570.
8. Gruvberger S., Ringnér M., Chen Y., Panavally S., Saal L.H., Borg A., Ferno M., Peterson C., Meltzer P.S. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res. 2001, 61:5979-5984.
9. Qian J., Chen Z., Lin J., Wang W., Cen J. Decreased expression of CCAAT/enhancer binding protein zeta (C/EBPzeta) in patients with different myeloid diseases. Leuk. Res. 2005, 29:1435-1441.
10. Pereira R.C., Delany A.M., Canalis E. CCAAT/enhancer binding protein homologous protein (DDIT3) induces osteoblastic cell differentiation. Endocrinology 2004, 145:1952-1960.
11. Coutts M., Cui K., Davis K.L., Keutzer J.C., Sytkowski A.J. Regulated expression and functional role of the transcription factor CHOP (GADD153) in erythroid growth and differentiation. Blood 1999, 93:3369-3378.
12. Landschulz W.H., Johnson P.F., Adashi E.Y., Graves B.J., McKnight S.L. Isolation of a recombinant copy of the gene encoding C/EBP. Genes Dev. 1988, 2:786-800.
13. Rosen E.D. The transcriptional basis of adipocyte development. Prostaglandins Leukot. Essent. Fatty Acids 2005, 73:31-34.
14. Regalo G., Resende C., Wen X., Gomes B., Duraes C., Seruca R., Carneiro F., Machado J.C. C/EBP alpha expression is associated with homeostasis of the gastric epithelium and with gastric carcinogenesis. Lab. Invest. 2010, 90:1132-1139.
15. Ron D., Habener J.F. CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. Genes Dev. 1992, 6:439-453.
16. Wang X.Z., Kuroda M., Sok J., Batchvarova N., Kimmel R., Chung P., Zinszner H., Ron D. Identification of novel stress-induced genes downstream of chop. EMBO J. 1998, 17:3619-3630.
17. Goransson M., Andersson M.K., Forni C., Stahlberg A., Andersson C., Olofsson A., Mantovani R., Aman P. The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ. Oncogene 2009, 28:270-278.
18. Stoesz S.P., Friedl A., Haag J.D., Lindstrom M.J., Clark G.M., Gould M.N. Heterogeneous expression of the lipocalin NGAL in primary breast cancers. Int. J. Cancer 1998, 79:565-572.
19. Shi H., Gu Y., Yang J., Xu L., Mi W., Yu W. Lipocalin 2 promotes lung metastasis of murine breast cancer cells. J. Exp. Clin. Cancer Res. 2008, 27:83.
20. Nielsen B.S., Borregaard N., Bundgaard J.R., Timshel S., Sehested M., Kjeldsen L. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut 1996, 38:414-420.
21. Lim R., Ahmed N., Borregaard N., Riley C., Wafai R., Thompson E.W., Quinn M.A., Rice G.E. Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int. J. Cancer 2007, 120:2426-2434.
22. Furutani M., Arii S., Mizumoto M., Kato M., Imamura M. Identification of a neutrophil gelatinase-associated lipocalin mRNA in human pancreatic cancers using a modified signal sequence trap method. Cancer Lett. 1998, 122:209-214.
23. Du Z.P., Lv Z., Wu B.L., Wu Z.Y., Shen J.H., Wu J.Y., Xu X.E., Huang Q., Shen J., Chen H.B., Li E.M., Xu L.Y. Neutrophil gelatinase-associated lipocalin and its receptor: independent prognostic factors of oesophageal squamous cell carcinoma. J. Clin. Pathol. 2010, 64:69-74.
24. Leng X., Ding T., Arlinghaus R. Requirement of lipocalin 2 for hematopoietic and solid tumor malignancies. Adv. Enzyme Regul. 2009, 49:142-146.
25. Deryugina E.I., Quigley J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006, 25:9-34.
26. Halbersztadt A., Haloń A., Pajak J., Robaczynski J., Rabczyński J., St Gabryś M. The role of matrix metalloproteinases in tumor invasion and metastasis. Ginekol. Pol. 2006, 77:63-71.
27. Yang X., Wang D., Dong W., Song Z., Dou K. Suppression of Na(+)/H(+) exchanger 1 by RNA interference or amiloride inhibits human hepatoma cell line SMMC-7721 cell invasion. Med. Oncol. 2011, 28:385-390.
28. Gao H., Schwartz R.C. C/EBPzeta (CHOP/Gadd153) is a negative regulator of LPS-induced IL-6 expression in B cells. Mol. Immunol. 2009, 47:390-397.
29. Seth P., Porter D., Lahti-Domenici J., Geng Y., Richardson A., Polyak K. Cellular and molecular targets of estrogen in normal human breast tissue. Cancer Res. 2002, 62:4540-4544.
30. Rong R., Montalbano J., Jin W., Zhang J., Garling M., Sheikh M.S., Huang Y. Oncogenic Ras-mediated downregulation of Gadd153/CHOP is required for Ras-induced cellular transformation. Oncogene 2005, 24:4867-4872.
31. Chen C., Nussenzweig A., Guo M., Kim D., Li G.C., Ling C.C. Down-regulation of gadd153 by c-myc in rat fibroblasts and its effect on cell growth and radiation-induced apoptosis. Oncogene 1996, 13:1659-1665.
32. Iannetti A., Pacifico F., Acquaviva R., Lavorgna A., Crescenzi E., Vascotto C., Tell G., Salzano A.M., Scaloni A., Vuttariello E., Chiappetta G., Formisano S., Leonardi A. The neutrophil gelatinase-associated lipocalin (NGAL), a NF-kappaB-regulated gene, is a survival factor for thyroid neoplastic cells. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:14058-14063.
33. Matsuo S., Yamazaki S., Takeshige K., Muta T. Crucial roles of binding sites for NF-kappaB and C/EBPs in IkappaB-zeta-mediated transcriptional activation. Biochem. J. 2007, 405:605-615.
34. Kim J., Namkung W., Yoon J.S., Jo M.J., Lee S.H., Kim K.H., Kim J.Y., Lee M.G. The role of translation elongation factor eEF1A in intracellular alkalinization-induced tumor cell growth. Lab. Invest. 2009, 89:867-874.
35. Putney L.K., Barber D.L. Expression profile of genes regulated by activity of the Na-H exchanger NHE1. BMC Genomics 2004, 5:46.
36. Bourguignon L.Y., Singleton P.A., Diedrich F., Stern R., Gilad E. CD44 interaction with Na+-H+ exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. J. Biol. Chem. 2004, 279:26991-27007.
37. Yan L., Borregaard N., Kjeldsen L., Moses M.A. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J. Biol. Chem. 2001, 276:37258-37265.
38. Yang X., Wang D., Dong W., Song Z., Dou K. Inhibition of Na(+)/H(+) exchanger 1 by 5-(N-ethyl-N-isopropyl) amiloride reduces hypoxia-induced hepatocellular carcinoma invasion and motility. Cancer Lett. 2010, 295:198-204.
39. He B., Deng C., Zhang M., Zou D., Xu M. Reduction of intracellular pH inhibits the expression of VEGF in K562 cells after targeted inhibition of the Na+/H+ exchanger. Leuk. Res. 2007, 31:507-514.
40. Lagana A., Vadnais J., Le P.U., Nguyen T.N., Laprade R., Nabi I.R., Noël J. Regulation of the formation of tumor cell pseudopodia by the Na(+)/H(+) exchanger NHE1. J. Cell Sci. 2000, 113(Pt 20):3649-3662.
41. Lu Y., Pang T., Wang J., Xiong D., Ma L., Li B., Li Q., Wakabayashi S. Down-regulation of P-glycoprotein expression by sustained intracellular acidification in K562/Dox cells. Biochem. Biophys. Res. Commun. 2008, 377:441-446.
42. Hanahan D., Wagner E.F., Palmiter R.D. The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer. Genes Dev. 2007, 21:2258-2270.
43. Veeck J., Niederacher D., An H., Klopocki E., Wiesmann F., Betz B., Galm O., Camara O., Durst M., Kristiansen G., Huszka C., Knuchel R., Dahl E. Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene 2006, 25:3479-3488.